Moderate-to-Severe Atopic Dermatitis: Targeting the Underlying Inflammatory Processes to Improve Patient Outcomes
Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology Associates of Chicago
Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health
University of Colorado School of Medicine
This case-based activity will cover the underlying causes of atopic dermatitis along with current and emerging systemic agents as part of the overall treatment plan.
This activity is intended for allergists, immunologists, and other healthcare professionals involved in the management of patients with atopic dermatitis.
- Review the role of type 2 inflammation in the pathogenesis of atopic dermatitis
- Identify common atopic and non-atopic comorbid conditions in patients with moderate-to-severe AD
- Evaluate clinical trial evidence on the efficacy and safety of currently available treatments for moderate-to-severe AD in adult and pediatric patients
- Utilize shared decision-making to develop comprehensive treatment plans for atopic dermatitis and related comorbid conditions
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the management of patients with atopic dermatitis.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Peter Lio, MD has served on the advisory board for the National Eczema Association, Modernizing Medicine, Johnson & Johnson, DermTap Inc., IntraDerm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, Dermveda, GPower Inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Verrica Pharmaceuticals Inc., Arbonne, Yobee Care Inc., and Bodewell. Dr. Lio is a stockholder in Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He has been a speaker for Pierre Fabre Dermatologie, Regeneron, Pfizer, and La Roche-Posay. He has been an investigator for La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), AOBiome LLC, Regeneron, AbbVie, and National Eczema Association. He has been a consultant for Exeltis, Theraplex, Odeza LLC, L’Oréal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Eli Lilly and Co., Unilever, Dermira, TopMD, Amyris Inc., Leo Pharma, and Burt’s Bees.
Mark Boguniewicz, MD has been a consultant with Regeneron, Sanofi-Genzyme, Lilly, Leo, and Pfizer. He has contracted research with Regeneron and Incyte.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Director of Medical and Scientific Services, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at firstname.lastname@example.org.
RELEASE DATE: March 11, 2021
EXPIRATION DATE: March 11, 2022
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at email@example.com.
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.